Search results
Results from the WOW.Com Content Network
Echopraxia is a hard science fiction novel by Canadian writer Peter Watts. [1] It is a "sidequel" to his 2006 novel, Blindsight, and the two novels make up the Firefall series.
Blindsight is a hard science fiction novel by Canadian writer Peter Watts, published by Tor Books in 2006. It won the Seiun Award for the best novel in Japanese translation (where it is published by Tokyo Sogensha) [2] and was nominated for the Hugo Award for Best Novel, [3] the John W. Campbell Memorial Award for Best Science Fiction Novel, [4] and the Locus Award for Best Science Fiction ...
Peter Watts (born January 25, 1958 [1]) is a Canadian science fiction author. He specializes in hard science fiction.He earned a Ph.D. from the University of British Columbia in 1991 from the Department of Zoology and Resource Ecology. [3]
The experimental device, known as Blindsight, "will enable even those who have lost both eyes and their optic nerve to see," Musk said in a post on X. Musk's Neuralink gets FDA's breakthrough ...
Neill Blomkamp (Afrikaans: [ˈnil ˈblɔmkamp]; born 17 September 1979) is a South African and Canadian film director and screenwriter.He is known as the co-writer and director of the science fiction action film District 9 (2009), for which he was nominated for the Academy Award for Best Adapted Screenplay, and the director of the dystopian science fiction action film Elysium (2013), which ...
Peter Watts' novel Blindsight has explored a scientific basis for vampires, depicting them as an evolutionary offshoot from humanity who were not the dominant species on the planet solely due to an evolutionary glitch making them averse to Euclidean geometry (right angles cause seizures in what is called "Crucifix Glitch", leading to them dying ...
It is the sequel to Skyward and second in a planned series of four books. It was published by Delacorte Press on November 26, 2019. [1] Plot summary.
Blindsight is an experimental medical device developed by Neuralink. [1] [2] It has received Breakthrough Device Designation from the US Food and Drugs Administration ...